sitagliptin/metforminhydrochlorid macleoda 50 mg/850 mg filmtabletten
metforminhydrochlorid laurus 1000 mg filmtabletten
metforminhydrochlorid laurus 850 mg filmtabletten
sitagliptin metforminhydrochlorid hennig 50 mg/1000 mg filmtabletten
sitagliptin metforminhydrochlorid hennig 50 mg/850 mg filmtabletten
ag-metformin tablet
angita pharma inc. - metformin hydrochloride - tablet - 500mg - metformin hydrochloride 500mg - biguanides
ag-metformin tablet
angita pharma inc. - metformin hydrochloride - tablet - 850mg - metformin hydrochloride 850mg - biguanides
glyburide and metformin hydrochloride- glyburide and metformin hydrochloride tablet
lake erie medical dba quality care products llc - glyburide (unii: sx6k58tvwc) (glyburide - unii:sx6k58tvwc), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glyburide 2.5 mg - glyburide and metformin hydrochloride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glyburide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (eg, as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions ). - known hypersensitivity to metformin hydrochloride or glyburide. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. - concomitant administration of bosentan. glyburide and metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, becau